Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALS peripheral motor nerve excitability study with riluzole, retigabine, and placebo
NL-OMON25730Active, not recruiting
- Sponsor
- Centre for Human Drug Research
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of riluzole, retigabine and Placebo-COD Research Private Ltd in amyotrophic lateral sclerosis (ALS) (3 arms), sponsored by Centre for Human Drug Research. Primary endpoint: Test-retest reliability of nerve excitability threshold tracking. Started Jun 2015; status: active, not recruiting.
02
Drugs
riluzoleretigabinePlacebo-COD Research Private Ltd
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON25730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25730.